Premium
Long‐term remission after intensive chemotherapy in advanced myelodysplastic syndromes is generally associated with restoration of polyclonal haemopoiesis
Author(s) -
Aivado Manuel,
Rong Astrid,
Germing Ulrich,
Gattermann Norbert,
Kobbe Guido,
Rieth Claudia,
Haas Rainer,
Aul Carlo
Publication year - 2000
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2000.02302.x
Subject(s) - polyclonal antibodies , haematopoiesis , monoclonal , chemotherapy , myelodysplastic syndromes , medicine , monoclonal antibody , oncology , immunology , biology , stem cell , bone marrow , antibody , genetics
The clonality of peripheral blood cells was assessed in eight female patients with myelodysplastic syndrome (MDS) by means of the human androgen receptor gene‐based assay (HUMARA). The patients were in complete remission for a median follow‐up time of 83 months after intensive chemotherapy. X‐chromosome inactivation patterns (XCIPs) indicated polyclonal haemopoiesis in five patients. Two patients had skewed lyonization (i.e. unbalanced XCIPs in both granulocytes and T cells) and one patient presented monoclonal granulocytes together with polyclonal T cells. We conclude that long‐term remission in MDS following intensive chemotherapy is usually associated with polyclonal haemopoiesis.